Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Logo
ASMB US​

Assembly Biosciences, Inc.(ASMB US)

$19.84-0.442.17%Ext:$19.04-0.804.05%(Market Closed · 23:47:22 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings
CategorizedChronologicalBy Owner

Financials & Metrics

FinancialsChartingShort InterestEmployees

SEC Filings

Financials(69)

Expand
  • 10-QQ2ended 30 Jun 202613 Aug
  • 10-QQ1ended 31 Mar 20267 May
  • 10-KFY 2025ended 31 Dec 202519 Mar
  • 10-QQ3ended 30 Sept 202510 Nov 2025
  • 10-QQ2ended 30 Jun 20256 Aug 2025
  • 10-QQ1ended 31 Mar 20258 May 2025
  • 10-KFY 2024ended 31 Dec 202420 Mar 2025
  • 10-QQ3ended 30 Sept 20247 Nov 2024
  • 10-QQ2ended 30 Jun 20248 Aug 2024
  • 10-QQ1ended 31 Mar 20248 May 2024
  • 10-KFY 2023ended 31 Dec 202328 Mar 2024
  • 10-QQ3ended 30 Sept 20238 Nov 2023
  • 10-QQ2ended 30 Jun 20239 Aug 2023
  • 10-QQ1ended 31 Mar 20234 May 2023
  • 10-KFY 2022ended 31 Dec 202222 Mar 2023

Events(191)

Expand
  • 8-K/AResults of Operations and Financial Condition14 Aug
  • 8-KCompletion of Acquisition or Disposition of Assets13 Aug
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers5 Jun
  • 8-KEntry into a Material Definitive Agreement26 May
  • 8-KRegulation FD Disclosure22 May
  • 8-KResults of Operations and Financial Condition7 May
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers30 Mar
  • 8-KResults of Operations and Financial Condition19 Mar
  • 8-KRegulation FD Disclosure8 Dec 2025
  • 8-KResults of Operations and Financial Condition10 Nov 2025
  • 8-KEntry into Material Agreement11 Aug 2025
  • 8-KAssembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor CandidateABI-5366Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes8 Aug 2025
  • 8-KResults of Operations and Financial Condition6 Aug 2025
  • 8-KOther Events25 Jun 2025
  • 8-KDirector/Officer Changes & Compensatory Arrangements9 Jun 2025

Insider Ownership(332)

Expand
  • 4Statement of changes in beneficial ownership18 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4GILEAD SCIENCES, INC.27 May
  • 4Statement of changes in beneficial ownership31 Mar
  • 4Statement of changes in beneficial ownership31 Mar

Beneficial Ownership(120)

Expand
  • SC 13G/AASSEMBLY BIOSCIENCES, INC.14 Aug
  • SC 13G/AASSEMBLY BIOSCIENCES, INC.13 Aug
  • SC 13G/AASSEMBLY BIOSCIENCES, INC.4 Aug
  • SC 13D/AASSEMBLY BIOSCIENCES, INC.27 May
  • SC 13GASSEMBLY BIOSCIENCES, INC.11 May
  • SC 13G/AASSEMBLY BIOSCIENCES, INC.9 Feb
  • SC 13GASSEMBLY BIOSCIENCES, INC.8 Dec 2025
  • SC 13GASSEMBLY BIOSCIENCES, INC.18 Aug 2025
  • SC 13G/AASSEMBLY BIOSCIENCES, INC.18 Aug 2025
  • SC 13GASSEMBLY BIOSCIENCES, INC.15 Aug 2025
  • SC 13GASSEMBLY BIOSCIENCES, INC.15 Aug 2025
  • SC 13D/AASSEMBLY BIOSCIENCES, INC.12 Aug 2025
  • SC 13GASSEMBLY BIOSCIENCES, INC.12 Aug 2025
  • SC 13G/AASSEMBLY BIOSCIENCES, INC.14 Feb 2025
  • SC 13GASSEMBLY BIOSCIENCES, INC.23 Dec 2024

Other Ownership(8)

Expand
  • 144Delaney William E IV3 Oct 2023
  • 144Okazaki Jason A3 Oct 2023
  • 144Delaney William E IV2 Aug 2023
  • 144Okazaki Jason A2 Aug 2023
  • 144Delaney William E IV30 May 2023
  • 144Okazaki Jason A23 May 2023
  • 144McHutchison John G23 May 2023
  • 144Delaney William E IV23 May 2023

Proxies(47)

Expand
  • DEFA14ADefinitive additional materials22 Apr
  • DEF 14ADefinitive proxy statement22 Apr
  • ARSAnnual report to security holders22 Apr
  • DEF 14ADefinitive proxy statement23 Apr 2025
  • DEFA14ADefinitive additional materials23 Apr 2025
  • ARSAnnual report to security holders23 Apr 2025
  • DEF 14ADefinitive proxy statement17 Apr 2024
  • ARSAnnual report to security holders17 Apr 2024
  • DEFA14ADefinitive additional materials17 Apr 2024
  • DEFA14ADefinitive additional materials21 Dec 2023
  • DEF 14ADefinitive proxy statement21 Dec 2023
  • PRE 14APreliminary proxy statement11 Dec 2023
  • DEF 14ADefinitive proxy statement12 Apr 2023
  • DEFA14ADefinitive additional materials12 Apr 2023
  • ARSAnnual report to security holders12 Apr 2023

Registrations(77)

Expand
  • S-8Registration statement (employee benefit plan)20 Aug
  • 424B5Prospectus filing (Rule 424(b)(5))22 May
  • 424B5Prospectus filing (Rule 424(b)(5))22 May
  • S-3Registration statement (primary offering)19 Mar
  • S-8Registration statement (employee benefit plan)19 Mar
  • 424B3Prospectus filing (Rule 424(b)(3))21 Nov 2025
  • S-3Registration statement (primary offering)14 Oct 2025
  • 424B5Prospectus filing (Rule 424(b)(5))11 Aug 2025
  • 424B5Prospectus filing (Rule 424(b)(5))11 Aug 2025
  • S-3MEFRegistration statement (additional securities, S-3)7 Aug 2025
  • S-8Registration statement (employee benefit plan)6 Aug 2025
  • S-3Registration statement (primary offering)20 Mar 2025
  • 424B5Prospectus filing (Rule 424(b)(5))7 Nov 2024
  • S-8Registration statement (employee benefit plan)8 Aug 2024
  • 424B5Prospectus filing (Rule 424(b)(5))18 Jun 2024

Filing Review Correspondence(15)

Expand
  • CORRESPFiling review correspondence25 Mar
  • CORRESPFiling review correspondence19 Nov 2025
  • CORRESPFiling review correspondence28 Mar 2025
  • CORRESPFiling review correspondence12 Apr 2023
  • CORRESPFiling review correspondence12 Jan 2021
  • CORRESPFiling review correspondence3 Sep 2020
  • CORRESPFiling review correspondence8 Jan 2018
  • CORRESPFiling review correspondence13 Jan 2016
  • CORRESPFiling review correspondence14 Jan 2015
  • CORRESPFiling review correspondence14 Dec 2010
  • UPLOADFiling review upload8 Dec 2010
  • UPLOADFiling review upload22 Nov 2010
  • UPLOADFiling review upload8 Nov 2010
  • UPLOADFiling review upload19 Oct 2010
  • UPLOADFiling review upload16 Aug 2010

SEC Orders And Notices(17)

Expand
  • EFFECTNotice of effectiveness30 Mar
  • EFFECTNotice of effectiveness24 Nov 2025
  • EFFECTNotice of effectiveness1 Apr 2025
  • EFFECTNotice of effectiveness14 Apr 2023
  • EFFECTNotice of effectiveness4 Sep 2020
  • EFFECTNotice of effectiveness10 Jan 2018
  • CT ORDERConfidential treatment order9 Jun 2017
  • EFFECTNotice of effectiveness19 Jan 2016
  • EFFECTNotice of effectiveness15 Jan 2015
  • CT ORDERConfidential treatment order13 Jan 2015
  • CT ORDERConfidential treatment order23 Jun 2014
  • CT ORDERConfidential treatment order18 Jul 2013
  • EFFECTNotice of effectiveness29 May 2012
  • EFFECTNotice of effectiveness10 Feb 2012
  • EFFECTNotice of effectiveness13 Jul 2011

Exempt Offerings(3)

Expand
  • DNotice of exempt offering of securities (Reg D)24 May 2010
  • D/ANotice of exempt offering of securities (Reg D, amendment)26 Apr 2010
  • DNotice of exempt offering of securities (Reg D)12 Mar 2010

Other(3)

Expand
  • SEC STAFF LETTERSEC STAFF LETTER26 Feb 2020
  • SEC STAFF LETTERSEC STAFF LETTER11 Feb 2020
  • CERTNASAUTO-GENERATED PAPER DOCUMENT15 Dec 2010